Abstract:A LTHOUGH THE MORtality rate for those with acute PE is low, certain patients are at high risk. Therefore, optimal management strategies should rely on risk stratification rather than “one-size-fits-all” treatment. In high-risk patients, the use of aggressive treatment could be justified. Despite the lack of definitive evidence, massive PE associated with cardiogenic shock, given the high mortality rate, is a widely accepted indication for thrombolysis. At the other extreme, the risks of thrombolysis are not justified in patients with an anatomically small PE that causes no elevation in RV afterload. The mortality rate for these patients is low, with most patients dying from underlying conditions rather than from PE. In a metaanalysis of 5 studies involving 1302 patients with PE treated by heparin followed by warfarin, the rate of death due to PE was only 1.5%. In such patients, the expected improvement in survival would be offset by the risk of life-threatening or disabling hemorrhage with thrombolytic treatment. The core of the thrombolysis debate focuses on hemodynamically stablepatientswithPEandsomeform of RV dysfunction. Because 30% to 50% of patients with PE present with echocardiographic evidence of RV dysfunction, the administration of a thrombolytic treatment toallof them would have significant implications. The arguments for thrombolysis in such patients are essentially the following:(1)RVdysfunctionisastrong prognostic factor in patients with acute PE; (2) the ability of thrombolytic agents to improve pulmonary reperfusionandenhanceRVfunction should translate into clinical benefit; and(3) resultsof several studieshave suggestedabeneficialeffectof thrombolysis in patients with acute PE and RV dysfunction. However, a more thoroughappraisalof thecurrentevidence does not support such conclusions. The following is based on a systematic review of the literature, whereby MEDLINE records from 1966 to 2004 were searched with the terms thrombolytictherapy, thrombolysis, fibrinolysis, thromboembolism, and pulmonary embolism to identify all studies evaluating thrombolytic therapy for PE.

Neuroimaging of Acute Ischemic Stroke: Multimodal Imaging Approach for Acute Endovascular Therapy

Endovascular Treatment for Acute Large Vessel Occlusion Due to Underlying Intracranial Atherosclerotic Disease

Brain Imaging for Stroke

Endovascular Therapy in Acute Ischemic Stroke: Time is Brain

Imaging Markers in Acute Phase of Stroke: Implications for Prognosis

Advanced Imaging for Acute Stroke Treatment Selection: CT, CTA, CT Perfusion, and MR Imaging

Advances in Functional Optical Coherence Tomography and Neuroimaging of Stroke

From “Time is Brain” to “Imaging is Brain”: A Paradigm Shift in the Management of Acute Ischemic Stroke

recent advances in imaging of acute ischemic stroke

Thrombolysis for pulmonary embolism in patients with right ventricular dysfunction: con.

Care Plan Assessment of Visual Status and Evaluated Vision among Nursing Home Residents

Dynamics of a class of immune networks. I. Global stability of idiotype interactions.

Imaging in acute ischaemic stroke: assessing findings in light of evolving therapies

Current State of Evidence for Neuroimaging Paradigms in Management of Acute Ischemic Stroke

Brain ischemia: CT and MRI techniques in acute ischemic stroke

Imaging Selection for Reperfusion Therapy in Acute Ischemic Stroke

Abstract Number ‐ 247: Multimodal imaging approach for the diagnosis of (ICAD): basic principles, current and future perspectives

Application of Multimodal MRI in the Diagnosis and Treatment of Patients with Acute Ischemic Stroke

Enhancement of anti-sheep erythrocyte plaque-forming cell levels by cimetidine in vivo.

Research on prognostic risk assessment model for acute ischemic stroke based on imaging and multidimensional data

Endovascular Treatment For Acute Ischemic Stroke: Updates And Future Implications